FI902935A0 - Menetelmä erytro-(E)-3,5-dihydroksi-7-[3'-(4''-fluorifenyyli)-1'-(1''-metyylietyyli)indol-2'-yyli]-hept-6-eenihapon valmistamiseksi - Google Patents

Menetelmä erytro-(E)-3,5-dihydroksi-7-[3'-(4''-fluorifenyyli)-1'-(1''-metyylietyyli)indol-2'-yyli]-hept-6-eenihapon valmistamiseksi

Info

Publication number
FI902935A0
FI902935A0 FI902935A FI902935A FI902935A0 FI 902935 A0 FI902935 A0 FI 902935A0 FI 902935 A FI902935 A FI 902935A FI 902935 A FI902935 A FI 902935A FI 902935 A0 FI902935 A0 FI 902935A0
Authority
FI
Finland
Prior art keywords
erythro
hept
indol
methylethyl
fluorophenyl
Prior art date
Application number
FI902935A
Other languages
English (en)
Swedish (sv)
Other versions
FI98063B (fi
FI98063C (fi
Inventor
Kau-Ming Chen
Prasad Koteswara Kapa
George T Lee
Oljan Repic
Petr Hess
Michel Crevoisier
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26945992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI902935(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of FI902935A0 publication Critical patent/FI902935A0/fi
Publication of FI98063B publication Critical patent/FI98063B/fi
Application granted granted Critical
Publication of FI98063C publication Critical patent/FI98063C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
    • C07C223/02—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI902935A 1988-10-13 1990-06-12 Menetelmä erytro-(E)-3,5-dihydroksi-7-[3'-(4''-fluorifenyyli)-1'-(1''-metyylietyyli)indol-2'-yyli]-hept-6-eenihapon valmistamiseksi FI98063C (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25747588A 1988-10-13 1988-10-13
US25747588 1988-10-13
US35553189A 1989-05-22 1989-05-22
US35553189 1989-05-22
PCT/EP1989/001201 WO1990003962A1 (en) 1988-10-13 1989-10-11 Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof
EP8901201 1989-10-11

Publications (3)

Publication Number Publication Date
FI902935A0 true FI902935A0 (fi) 1990-06-12
FI98063B FI98063B (fi) 1996-12-31
FI98063C FI98063C (fi) 1997-04-10

Family

ID=26945992

Family Applications (1)

Application Number Title Priority Date Filing Date
FI902935A FI98063C (fi) 1988-10-13 1990-06-12 Menetelmä erytro-(E)-3,5-dihydroksi-7-[3'-(4''-fluorifenyyli)-1'-(1''-metyylietyyli)indol-2'-yyli]-hept-6-eenihapon valmistamiseksi

Country Status (24)

Country Link
EP (2) EP0562643A3 (fi)
JP (1) JP2853227B2 (fi)
KR (1) KR0162656B1 (fi)
AT (1) ATE99281T1 (fi)
AU (1) AU636122B2 (fi)
BG (1) BG60555B1 (fi)
CA (1) CA2000553C (fi)
CZ (1) CZ283316B6 (fi)
DE (1) DE68911834T2 (fi)
DK (1) DK175073B1 (fi)
ES (1) ES2060712T3 (fi)
FI (1) FI98063C (fi)
HK (1) HK49496A (fi)
HU (1) HU207993B (fi)
IE (2) IE63477B1 (fi)
IL (1) IL91941A (fi)
MY (1) MY105067A (fi)
NO (1) NO174623C (fi)
NZ (1) NZ230973A (fi)
RO (1) RO109732B1 (fi)
SG (1) SG139553A1 (fi)
SK (1) SK579789A3 (fi)
WO (1) WO1990003962A1 (fi)
YU (1) YU48466B (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290946A (en) * 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) * 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
CA2027179A1 (en) * 1989-10-10 1991-04-11 Barry C. Ross Chemical compounds
DE4424525A1 (de) * 1994-07-12 1995-01-26 Elmar Meyer Dauermagnet-Kolbenmotor
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
JP2003535077A (ja) 2000-05-26 2003-11-25 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド インドール誘導体を製造する方法、および該方法の中間体
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
KR20050114282A (ko) * 2003-04-24 2005-12-05 다이셀 가가꾸 고교 가부시끼가이샤 광학 활성의 디히드록시헵텐산 에스테르의 분리 방법
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
EP1726583A3 (en) 2003-06-18 2007-05-09 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal form LXXIX, processes for preparing it, compositions containing it and methods of using it.
EP1722780A4 (en) 2003-11-26 2008-12-17 Univ Duke METHOD FOR PREVENTING OR TREATING GLAUCOMA
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ES2327668T3 (es) 2006-04-20 2009-11-02 F.I.S. Fabbrica Italiana Sintetici S.P.A. Procedimiento para la preparacion de sal sodica de fluvastatina.
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CN104902892A (zh) 2012-02-02 2015-09-09 悉尼大学 泪液膜稳定性的改进
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB945536A (en) * 1961-09-08 1964-01-02 Istituto Chemioterapico Method of preparing ª -amino-acroleins
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) * 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US4571428A (en) * 1983-07-08 1986-02-18 Sandoz, Inc. 6-Substituted-4-hydroxy-tetrahydropyran-2-ones
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
JPS61502467A (ja) * 1984-06-22 1986-10-30 サンド・アクチエンゲゼルシヤフト メバロノラクトンのピラゾ−ル同族体およびその誘導体、それらの製造方法ならびに用途
HU198005B (en) * 1984-12-04 1989-07-28 Sandoz Ag Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
EP0244364A3 (en) * 1986-04-30 1992-04-01 Sandoz Ag Preparation of olefinic compounds
PT85662B (pt) * 1986-09-10 1990-06-29 Sandoz Sa Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem

Also Published As

Publication number Publication date
RO109732B1 (ro) 1995-05-30
HU896048D0 (en) 1990-11-28
YU197389A (en) 1990-12-31
HUT53860A (en) 1990-12-28
CA2000553A1 (en) 1990-04-13
ATE99281T1 (de) 1994-01-15
DE68911834T2 (de) 1994-06-23
AU636122B2 (en) 1993-04-22
JP2853227B2 (ja) 1999-02-03
NO902598D0 (no) 1990-06-12
IE940109L (en) 1990-04-13
ES2060712T3 (es) 1994-12-01
DK144690D0 (da) 1990-06-13
CZ283316B6 (cs) 1998-02-18
IL91941A0 (en) 1990-06-10
DE68911834D1 (de) 1994-02-10
AU4344889A (en) 1990-05-01
EP0562643A2 (en) 1993-09-29
CZ579789A3 (en) 1997-11-12
CA2000553C (en) 2001-12-04
SK280845B6 (sk) 2000-08-14
NO902598L (no) 1990-08-07
JPH03501735A (ja) 1991-04-18
DK144690A (da) 1990-06-13
IE63477B1 (en) 1995-04-19
YU48466B (sh) 1998-08-14
NO174623B (no) 1994-02-28
MY105067A (en) 1994-07-30
DK175073B1 (da) 2004-05-24
IE893277L (en) 1990-04-13
KR900701723A (ko) 1990-12-04
FI98063B (fi) 1996-12-31
NZ230973A (en) 1993-03-26
SK579789A3 (en) 2000-08-14
SG139553A1 (en) 2008-02-29
FI98063C (fi) 1997-04-10
IL91941A (en) 1994-10-21
EP0562643A3 (en) 1994-05-18
WO1990003962A1 (en) 1990-04-19
KR0162656B1 (ko) 1999-01-15
BG60555B1 (en) 1995-08-28
EP0363934B1 (en) 1993-12-29
NO174623C (no) 1994-06-08
HK49496A (en) 1996-03-29
EP0363934A1 (en) 1990-04-18
HU207993B (en) 1993-07-28

Similar Documents

Publication Publication Date Title
FI902935A0 (fi) Menetelmä erytro-(E)-3,5-dihydroksi-7-[3'-(4''-fluorifenyyli)-1'-(1''-metyylietyyli)indol-2'-yyli]-hept-6-eenihapon valmistamiseksi
DK77090D0 (da) Immunmodulerende azaspiraner
EP0378518A3 (en) Adenosine derivatives having pharmaceutical activity as antihypertensives
ATE219766T1 (de) N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
GR3004902T3 (fi)
KR880000400A (ko) 융합된 사이클릭 아제핀-2-온 유도체 및 그의 제조방법
GB8602116D0 (en) Organic compounds
BR8801875A (pt) Composicao copolimera
IE890514L (en) Therapeutic agents for the treatment of peptic ulcer disease
KR830006288A (ko) 카바펜암과 카바펜-2-엠의 제조방법
DK508484D0 (da) N-substituerede isoquinolinderivater og farmaceutisk praeparat indeholdende dem
DK0427518T3 (da) NMDA-blokerende forbindelser, farmaceutiske præparater, deres fremstilling og anvendelse
ES2012687A6 (es) Procedimiento de preparacion de derivados 1,4-dihidro-piridinas.
ES8505653A1 (es) Procedimiento para preparar un n-alquil-(3 o 4)piperidinil benzoato
ES2000865A6 (es) Procedimiento para la obtencion de derivados del acido 2,6-dimetil-4-(3-nitrofenil)-1,4-dihidropiridin-3,5-dicarboxilico
EP0260605A3 (en) Dihydropyridine-5-phosphonic acid cyclic ester
PT83599B (en) Process for preparing 1,4-dihydropyridine derivatives
CA1262906C (en) 3-(2-FUROYL)-5-ALCOXYCARBONYL-2,6-DIMETHYL-4-(2-NITROPHENYL)-1,4-DIHYDROPYRIDINES, CALCIUM ANTAGONISTS
ES2039260T3 (es) Derivado de 4-oxo-1,3-benzodioxano.
ES8801291A1 (es) Un procedimiento para la preparacion de nuevos derivados de beta-lactama.
EP0370974A3 (en) Process for preparing heterocyclic derivatives

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: NOVARTIS AG

FG Patent granted

Owner name: NOVARTIS AG